Representatives from over 17 federal agencies and offices convened to provide updates on their efforts to advance the action items outlined in the National HIV/AIDS Strategy. They also discussed preliminary plans for the 2026-2030 strategy.

The CDC published data from the 2022 cycle of the Medical Monitoring Project (MMP) which reports nationally representative estimates of behavioral and clinical characteristics of adults with diagnosed HIV infection in the United States. This report provides information critical for achieving national HIV-related goals, including data used to monitor five National HIV/AIDS Strategy (2022-2025) quality of life indicators and HIV stigma.

HIV and substance use have been linked for decades. In a NIDA blog post, the directors of NIDA and NIAID write about a 2017 study that found overdose deaths among people with HIV in New York City were more than double the city’s overall rate. Most victims were engaged in HIV care, highlighting missed overdose prevention opportunities.

Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, according to an exploratory analysis from a large international clinical trial primarily funded by the National Institutes of Health (NIH). The findings were presented at the 2024 International AIDS Conference in Munich, Germany.

Visit the website to read the full blogs!